{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:39:03Z","timestamp":1792492743251,"version":"4.5.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is a life-threatening disease of varied etiologies. Although PAH has no curative treatment, a greater understanding of pathophysiology, technological advances resulting in early diagnosis, and the availability of several newer drugs have improved the outlook for patients with PAH. Sildenafil is one of the therapeutic agents used extensively in the treatment of PAH in children, as an off-label drug. In 2012, the United States Food and Drug Administration (USFDA) issued a warning regarding the of use high-dose sildenafil in children with PAH. This has led to a peculiar situation where there is a paucity of approved therapies for the management of PAH in children and the use of the most extensively used drug being discouraged by the regulator. This article provides a review of the use of sildenafil in the treatment of PAH in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.159421","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T04:50:25Z","timestamp":1435294225000},"page":"181-192","source":"Crossref","is-referenced-by-count":33,"title":["Sildenafil in pediatric pulmonary arterial hypertension"],"prefix":"10.4103","volume":"61","author":[{"given":"AK","family":"Dhariwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SB","family":"Bavdekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20240205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/ers.09.16","article-title":"Advances in therapies for pediatric pulmonary arterial hypertension","volume":"3","author":"Tissot","year":"2009","journal-title":"Expert Rev Respir Med"},{"key":"R4-7-20240205","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R5-7-20240205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/2045-8932.83456","article-title":"A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI pediatric taskforce, Panama 2011","volume":"1","author":"Cerro","year":"2011","journal-title":"Pulm Circ"},{"key":"R6-7-20240205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/ers.09.71","article-title":"Clinical use of sildenafil in pulmonary artery hypertension","volume":"4","author":"Singh","year":"2010","journal-title":"Expert Rev Respir Med"},{"key":"R7-7-20240205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R9-7-20240205","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.125.2.580","article-title":"Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension","volume":"125","author":"Leuchte","year":"2004","journal-title":"Chest"},{"key":"R10-7-20240205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/2249-4847.105958","article-title":"Is Sildenafil an effective therapy in the management of persistent pulmonary hypertension?","volume":"1","author":"Yaseen","year":"2012","journal-title":"Clin Neonatol"},{"key":"R11-7-20240205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00246-009-9523-1","article-title":"Sildenafil for the treatment of pulmonary hypertension in pediatric patients","volume":"30","author":"Huddleston","year":"2009","journal-title":"Pediatr Cardiol"},{"key":"R14-7-20240205","doi-asserted-by":"crossref","first-page":"F223","DOI":"10.1136\/adc.2009.180091","article-title":"The management of neonatal pulmonary hypertension","volume":"97","author":"Dhillon","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R15-7-20240205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.2010.03831.x","article-title":"Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension","volume":"71","author":"Vachiery","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R16-7-20240205","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jpeds.2009.06.012","article-title":"Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension","volume":"155","author":"Steinhorn","year":"2009","journal-title":"J Pediatr"},{"key":"R17-7-20240205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1542\/peds.2006-2567","article-title":"Intratracheal sildenafil in the newborn with pulmonary hypertension","volume":"119","author":"Martell","year":"2007","journal-title":"Pediatrics"},{"key":"R18-7-20240205","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00246-013-0811-4","article-title":"Safety and tolerability of targeted therapies for pulmonary hypertension in children","volume":"35","author":"Roldan","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"R19-7-20240205","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"R20-7-20240205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00246-012-0598-8","article-title":"Evolving management of pediatric pulmonary arterial hypertension: Impact of phosphodiesterase inhibitors","volume":"34","author":"Wardle","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"R21-7-20240205","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1081\/CLT-100102015","article-title":"Sildenafil: Clinical toxicology profile","volume":"38","author":"Krenzelok","year":"2000","journal-title":"J Toxicol Clin Toxicol"},{"key":"R22-7-20240205","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijcard.2004.09.002","article-title":"Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension","volume":"100","author":"Karatza","year":"2005","journal-title":"Int J Cardiol"},{"key":"R23-7-20240205","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/adc.88.9.827","article-title":"Sildenafil as a treatment for pulmonary hypertension","volume":"88","author":"Carroll","year":"2003","journal-title":"Arch Dis Child"},{"key":"R25-7-20240205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/archdischild-2013-303981","article-title":"Paediatric pulmonary hypertension and sildenafil: Current practice and controversies","volume":"98","author":"Wardle","year":"2013","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"R26-7-20240205","first-page":"1219","article-title":"Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Galie","year":"2009","journal-title":"Eur Respir J"},{"key":"R27-7-20240205","first-page":"3","article-title":"Oral sildenafil treatment in children with pulmonary arterial hypertension: Results of a double-blind, placebo-controlled, dose-ranging study","volume":"34","author":"Barst","year":"2009","journal-title":"Eur Respir J"},{"key":"R28-7-20240205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/PCC.0000000000000007","article-title":"Sildenafil exposure and hemodynamic effect after fontan surgery","volume":"15","author":"Tunks","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"R29-7-20240205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/ajt.12552","article-title":"The use of oral sildenafil for management of right ventricular dysfunction after pediatric heart transplantation","volume":"14","author":"Singh","year":"2014","journal-title":"Am J Transplant"},{"key":"R31-7-20240205","first-page":"19","article-title":"Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children","volume":"23","author":"Farah","year":"2013","journal-title":"Iran J Pediatr"},{"key":"R32-7-20240205","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PCC.0b013e31828aa5ee","article-title":"Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery","volume":"14","author":"Hill","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"R33-7-20240205","first-page":"19","article-title":"Magnesium sulphate versus sildenafil in the treatment of persistent pulmonary hypertension of the newborn","volume":"1","author":"Shaltout","year":"2012","journal-title":"Int J Clin Pediatr"},{"key":"R34-7-20240205","first-page":"238","article-title":"Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery","volume":"38","author":"Palma","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"R35-7-20240205","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.110.981746","article-title":"Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: A randomized, double-blind, placebo-controlled, crossover trial","volume":"123","author":"Goldberg","year":"2011","journal-title":"Circulation"},{"key":"R36-7-20240205","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-010-2065-4","article-title":"Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease","volume":"37","author":"Fraisse","year":"2011","journal-title":"Intensive Care Med"},{"key":"R37-7-20240205","first-page":"S64","article-title":"Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at Queen Sirikit National Institute of Child Health","volume":"94","author":"Khorana","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"R38-7-20240205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1047951110001745","article-title":"Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease","volume":"21","author":"Humpl","year":"2011","journal-title":"Cardiol Young"},{"key":"R39-7-20240205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/tropej\/fmq091","article-title":"A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: A randomized controlled trial","volume":"57","author":"Uslu","year":"2011","journal-title":"J Trop Pediatr"},{"key":"R40-7-20240205","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00246-009-9632-x","article-title":"Postoperative use of oral sildenafil in pediatric patients with congenital heart disease","volume":"31","author":"Uhm","year":"2010","journal-title":"Pediatr Cardiol"},{"key":"R41-7-20240205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejcts.2010.01.045","article-title":"Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children","volume":"38","author":"Nemoto","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"R42-7-20240205","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1017\/S1047951110000648","article-title":"Sildenafil in the management of the failing Fontan circulation","volume":"20","author":"Reinhardt","year":"2010","journal-title":"Cardiol Young"},{"key":"R43-7-20240205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1747-0803.2008.00237.x","article-title":"Sildenafil increases systemic saturation and reduces pulmonary artery pressure in patients with failing fontan physiology","volume":"4","author":"Morchi","year":"2009","journal-title":"Congenit Heart Dis"},{"key":"R44-7-20240205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0885066608321389","article-title":"Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease","volume":"23","author":"Lee","year":"2008","journal-title":"J Intensive Care Med"},{"key":"R45-7-20240205","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1164\/rccm.200605-694OC","article-title":"Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children","volume":"174","author":"Namachivayam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R46-7-20240205","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.athoracsur.2006.08.043","article-title":"Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan","volume":"82","author":"Uzun","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"R47-7-20240205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FJC.0b013e318213aac2","article-title":"Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation","volume":"58","author":"Watt","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"R48-7-20240205","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1067\/mtc.2002.125265","article-title":"Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises","volume":"124","author":"Atz","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R49-7-20240205","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2012-0587","article-title":"Oral sildenafil as a rescue therapy in presumed acute pulmonary hypertensive crisis","volume":"131","author":"Maxted","year":"2013","journal-title":"Pediatrics"},{"key":"R52-7-20240205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/archdischild-2012-303333","article-title":"The utility of sildenafil in pulmonary hypertension: A focus on bronchopulmonary dysplasia","volume":"98","author":"Wardle","year":"2013","journal-title":"Arch Dis Child"},{"key":"R53-7-20240205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/jp.2011.131","article-title":"Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: Any benefits?","volume":"32","author":"Nyp","year":"2012","journal-title":"J Perinatol"},{"key":"R54-7-20240205","doi-asserted-by":"crossref","first-page":"F467","DOI":"10.1136\/adc.2008.153684","article-title":"Sildenafil use in congenital diaphragmatic hernia","volume":"94","author":"Hunter","year":"2009","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R55-7-20240205","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1161\/CIRCULATIONAHA.104.473371","article-title":"Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study","volume":"111","author":"Humpl","year":"2005","journal-title":"Circulation"},{"key":"R56-7-20240205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000076684","article-title":"Treatment of primary pulmonary hypertension with oral sildenafil","volume":"71","author":"Karatza","year":"2004","journal-title":"Respiration"},{"key":"R57-7-20240205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"R58-7-20240205","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"R59-7-20240205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.2006.01692.x","article-title":"First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension","volume":"36","author":"Lunze","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"R60-7-20240205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3046.2006.00606.x","article-title":"Bosentan and sildenafil: Should the combination therapy be a valid alternative in childhood to prostacyclin infusion?","volume":"11","author":"Brancaccio","year":"2007","journal-title":"Pediatr Transplant"},{"key":"R61-7-20240205","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1047951105002155","article-title":"Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption","volume":"16","author":"Lammers","year":"2006","journal-title":"Cardiol Young"},{"key":"R62-7-20240205","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1007\/s00134-003-2016-4","article-title":"Intravenous sildenafil and inhaled nitric oxide: A randomised trial in infants after cardiac surgery","volume":"29","author":"Stocker","year":"2003","journal-title":"Intensive Care Med"},{"key":"R63-7-20240205","doi-asserted-by":"crossref","first-page":"II167","DOI":"10.1161\/01.cir.0000087384.76615.60","article-title":"Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease","volume":"108","author":"Schulze-Neick","year":"2003","journal-title":"Circulation"},{"key":"R64-7-20240205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jpeds.2008.09.021","article-title":"Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease","volume":"154","author":"Mourani","year":"2009","journal-title":"J Pediatr"},{"key":"R65-7-20240205","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1542\/peds.2005-0523","article-title":"Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded trial study","volume":"117","author":"Baquero","year":"2006","journal-title":"Pediatrics"},{"key":"R66-7-20240205","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1164\/rccm.201210-1928PP","article-title":"Pediatric Pulmonary Hypertension Network (PPHNet). Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for thetreatment of pediatric pulmonary hypertension","volume":"187","author":"Abman","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R67-7-20240205","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1164\/rccm.201301-0159LE","article-title":"Temporal trends in use of sildenafil among pediatric patients","volume":"188","author":"Bhutta","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R68-7-20240205","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.113.005698","article-title":"STARTS-2: Long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension","volume":"129","author":"Barst","year":"2014","journal-title":"Circulation"},{"key":"R69-7-20240205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4103\/0019-5359.37789","article-title":"Novel phosphodiesterase-5 inhibitors: Current indications and future directions","volume":"61","author":"Sharma","year":"2007","journal-title":"Indian J Med Sci"},{"key":"R70-7-20240205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00246-013-0840-z","article-title":"Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension","volume":"35","author":"Sabri","year":"2014","journal-title":"Pediatr Cardiol"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201561030-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:45Z","timestamp":1786650045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201561030-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.159421","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}